





Item 7.01 Regulation FD Disclosure.

Attached as Exhibits 99.1 and 99.2 to this Current Report is the form of presentation and poster session, respectively, that Cellular Biomedicine Group, Inc. (the “Company”) used in connection with the Company’s presentation of its developments of haMPC as a disease modifying therapy for Osteoarthritis patients, including a comparative preclinical study on the efficiency and biodistribution of autologous, allogeneic and xenogeneic adipose mesenchymal stem cells on osteoarthritis and interim three-month safety data for the Company’s Phase I clinical trial for AlloJoin™ Off-the-Shelf Allogeneic Stem Cell Therapy for Knee Osteoarthritis at the World Stem Cell Summit held in West Palm Beach, Florida on December 8, 2016.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Presentation

99.2 Poster Session



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cellular Biomedicine Group,  
Inc.

Date: December 8, 2016 By: /s/ Bizuo (Tony) Liu  
Bizuo (Tony) Liu  
Chief Financial Officer